SR-3306

SR-3306 is a selective, potent, and highly brain-penetrant small molecule inhibitor of c-jun-N-terminal kinase (JNK), belonging to the aminopyrimidine chemical class[1][4][10]. It acts as an ATP-competitive inhibitor predominantly of JNK3 and JNK2, with an IC50 near 200 nM, and displays >100-fold selectivity over p38 MAPK and other kinases[4][10]. Preclinical studies demonstrate that SR-3306 offers significant neuroprotective effects in models of Parkinson’s disease, protecting dopaminergic neurons in the substantia nigra pars compacta and reducing motor deficits by nearly 90% in animal models[1][2][5][6]. It is also reported to influence energy balance and food intake in rodent models[8]. SR-3306 was originally developed at The Scripps Research Institute and was later licensed to OPKO Health for global clinical development as a potential neuroprotective therapy for Parkinson's disease[9][12].

Brand names

SR-3306SR3306SR 3306

Other names

SR3306SR-3306SR 3306